São Paulo - Delayed Quote BRL

Dr. Reddy's Laboratories Limited (R1DY34.SA)

Compare
13.63
0.00
(0.00%)
At close: January 27 at 1:23:42 PM GMT-3
Currency in BRL All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
311,305,000.00
279,164,000.00
245,879,000.00
214,391,000.00
189,722,000.00
Cost of Revenue
126,657,000.00
115,557,000.00
106,536,000.00
100,551,000.00
86,645,000.00
Gross Profit
184,648,000.00
163,607,000.00
139,343,000.00
113,840,000.00
103,077,000.00
Operating Expense
116,704,000.00
98,299,000.00
80,289,000.00
77,921,000.00
70,167,000.00
Operating Income
67,944,000.00
65,308,000.00
59,054,000.00
35,919,000.00
32,910,000.00
Net Non Operating Interest Income Expense
-6,000.00
567,000.00
-248,000.00
7,000.00
-144,000.00
Other Income Expense
4,808,000.00
5,995,000.00
1,561,000.00
-3,628,000.00
-6,353,000.00
Pretax Income
72,746,000.00
71,870,000.00
60,367,000.00
32,298,000.00
26,413,000.00
Tax Provision
18,303,000.00
16,186,000.00
15,300,000.00
8,730,000.00
9,175,000.00
Net Income Common Stockholders
53,676,000.00
55,684,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Diluted NI Available to Com Stockholders
53,676,000.00
55,684,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Basic EPS
10.74
11.15
9.05
4.74
3.46
Diluted EPS
10.72
11.13
9.03
4.72
3.46
Basic Average Shares
4,996,879.41
4,991,811.08
4,981,046.69
4,976,351.34
4,975,330.19
Diluted Average Shares
5,005,096.71
5,001,226.07
4,991,645.09
4,990,048.69
4,989,481.22
Total Operating Income as Reported
69,155,000.00
67,729,000.00
57,144,000.00
29,476,000.00
24,280,000.00
Total Expenses
243,361,000.00
213,856,000.00
186,825,000.00
178,472,000.00
156,812,000.00
Net Income from Continuing & Discontinued Operation
53,676,000.00
55,684,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Normalized Income
50,225,134.34
51,181,040.00
44,173,750.00
26,729,630.00
21,679,450.00
Interest Income
2,760,000.00
2,278,000.00
1,180,000.00
965,000.00
826,000.00
Interest Expense
2,766,000.00
1,711,000.00
1,428,000.00
958,000.00
970,000.00
Net Interest Income
-6,000.00
567,000.00
-248,000.00
7,000.00
-144,000.00
EBIT
75,512,000.00
73,581,000.00
61,795,000.00
33,256,000.00
27,383,000.00
EBITDA
91,729,000.00
88,422,000.00
74,431,000.00
45,080,000.00
40,179,000.00
Reconciled Cost of Revenue
126,657,000.00
115,557,000.00
106,536,000.00
100,551,000.00
86,645,000.00
Reconciled Depreciation
16,217,000.00
14,841,000.00
12,636,000.00
11,824,000.00
12,796,000.00
Net Income from Continuing Operation Net Minority Interest
53,676,000.00
55,684,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Total Unusual Items Excluding Goodwill
4,611,000.00
5,848,000.00
1,191,000.00
-4,331,000.00
-6,833,000.00
Total Unusual Items
4,611,000.00
5,848,000.00
1,191,000.00
-4,331,000.00
-6,833,000.00
Normalized EBITDA
87,118,000.00
82,574,000.00
73,240,000.00
49,411,000.00
47,012,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
1,160,134.34
1,345,040.00
297,750.00
-1,169,370.00
-2,391,550.00
3/31/2021 - 10/20/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade